Erill N1, Colomer A1, Calvo M3, Vidal A2, Román R1, Verdú M2, Cordon-Cardo C4, Puig X1,2.
1BIOPAT, 2HISTOPAT Laboratoris, 3Statistics Dept. of the Universitat de Barcelona, Spain; and 4Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.
Chromosome 18q allelic loss (c18q LOH) seems to have prognostic significance in stage II colorectal carcinoma. In our laboratory […]
Anna Colomer,1 Nadina Erill,1 Montse Verdú,2 Ruth Roman,1 August Vidal,1,2 Carlos Cordon-Cardo,1,3 Xavier Puig1,2
1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; and 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.
Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response […]
I. Erill a, S. Campoy b, N. Erill c, J. Barbé b, J. Aguiló a
a Biomedical Applications Group, Centro Nacional de Microelectrónica (CNN.IMB); b Departament de Genètica i Microbiologia / Centre de Recerca en Sanitat Animal (CReSA) Universitat Autònoma de Barcelona; c BIOPAT. Biopatología molecular. Grup Assistència.
N. Hannaoui, N. Erill*, A. Colomer*, E. Vicente, A. Peña, E. Gómez, M. Verdú*, R. Román*, X. Puig*, JM. Banús
Institut Català d’Urologia i Nefrologia. * BIOPAT. Biopatologia molecular, S.L. Grup Assistència.
Verdú M1, Colomer A2, Román R2, Erill N2, Moreno A1, Cordón-Cardo C1,2, Puig X1,2.
1HISTOPAT Laboratoris & 2BIOPAT. Grup Assistència. Barcelona (Spain).
HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) […]